Exclusive sales agreement contract signed with Mundipharma for CartiLife®.
Autologous Chondrocyte Cell Theraphy CartiLife registered for sale.
Human tissue model registered as OECD TG.
CartiLife core technology (pellet-type cartilage) patent registered in the EU.
BSP-11 core technology patented.
CartiLife core technology (pellet-type cartilage) patent registered in Japan.
Company listed on the KOSDAQ Market.
CartiLife core technology (pellet-type cartilage) patent registered in USA.
Cornea irritation test using MCTT HCETM registered on the OECD WNT.
Stim Mobil Gel core technology patent registered.
CartiLife core technology (pellet-type cartilage) patent registered
Special award received in Lush Prize Animal Substitution Test Field.
CartiLife approved as 'New Excellent Technology' (NET) by the Korea Health Industry Development Institute
Company registered as a 'K-BrainPower' company by the Korean Ministry of Trade, Industry and Energy.
Costal cartilage core technology patent registered in USA.
Costal cartilage core technology patent registered in EU.
Registered on the Patent List for Medicine at the Korea Food & Drugs Administration
Changed Name of Company to Biosolution Co., Ltd.
Allogeneic keratinocyte therapy product KeraHeal-Allo approved for sale.
Accreditation of Excellent Academic Contribution for the Implementation of Bioethics (Korean Society for Alternative to Animal Experiments)
Manufacturing plant (GMP) expansion transfer.
Costal cartilage core technology patented in China.
KeraHeal approval after re-evaluation.
Changed company name to MCTT BIO Co., Ltd.
Launched STeM水, Extract from Stem Cell Culture Media
KeraHeal Approved for Coverage under the Occupational Health and Safety Insurance
Received License for KeraHeal, an Autologous Keratinocyte Therapy Product
Established Company and Received Approval for the R&D Center